Detection of neuraminidase-inhibiting antibodies for measurement of Influenza vaccine immunogenicity

Similar documents
Correlates of Protection for Flu vaccines and Assays Overview. by Simona Piccirella, PhD Chief Executive Officer

Overview of assays for influenza vaccines immunology evaluation

Influenza or flu is a

Ralf Wagner Paul-Ehrlich-Institut

Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC

Identification of Microbes Lecture: 12

Influenza A H1N1 HA ELISA Pair Set

Overview and Future Plans: Laboratory Working Group. John Wood and Othmar Engelhardt CONSISE Open Meeting, Cape Town South Africa 4 September 2013

Influenza A H1N1 (Swine Flu 2009) Hemagglutinin / HA ELISA Pair Set

2009 H1N1 Influenza ( Swine Flu ) Hemagglutinin ELISA kit

7/14/2014. Multiple immune effector mechanisms contribute to protection influenza. What is a correlate of protection?

Incorporating virologic data into seasonal and pandemic influenza vaccines

A Common Surface Antigen in Influenza Viruses from Human and Avian Sources

The Assay of Influenza Antineuraminidase Activity by an Elution Inhibition Technique

CHAPTER 4 IMMUNOLOGICAL TECHNIQUES

H5N1 ( Avian Flu ) Hemagglutinin ELISA Pair Set

HIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual)

DRAFT. c 2.G Serological diagnosis of influenza by microneutralization assay 2.G

Influenza Virus Genotypes Circulating In Central Greece During And Vaccine Strain Match

Supporting Information

Application of the Single Radial Diffusion Test for Assay of

In the Name of God. Talat Mokhtari-Azad Director of National Influenza Center

Vaccine. Design and Manufacturing. Liting Bi.

Influenza A H7N9 (A/Anhui/1/2013) Hemagglutinin / HA ELISA Pair Set

Reagents for the Typing of Human Influenza Isolates 2011

This product was developed by the Victorian Infectious Diseases Reference Laboratory (VIDRL) in its capacity as a WHO Collaborating Centre for

INFLUENZA EVOLUTION: Challenges for diagnosis

REAGENTS FOR THE TYPING OF HUMAN INFLUENZA ISOLATES 2017

Inhibition of Virus Release by Antibodies to Surface Antigens of

STUDIES OF THE HEMAGGLUTININ OF HAEMOPHILUS PERTUSSIS HIDEO FUKUMI, HISASHI SHIMAZAKI, SADAO KOBAYASHI AND TATSUJI UCHIDA

Influenza B Hemagglutinin / HA ELISA Pair Set

Vaccine 34 (2016) Contents lists available at ScienceDirect. Vaccine. journal homepage:

Herpes Simplex Virus 2 IgM HSV 2 IgM

Herpes Simplex Virus 2 IgG HSV 2 IgG

Isolation of Influenza C Virus from Pigs and Experimental Infection of Pigs with Influenza C Virus

INFLUENZA VIRUS. INFLUENZA VIRUS CDC WEBSITE

Clinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY

Human Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set

Update on influenza monitoring and vaccine development

Enzyme-Linked Immunosorbent Assay for Mumps and

HARMONISATION OF REQUIREMENTS FOR INFLUENZA VACCINES

See external label 96 tests HSV 2 IgA. Cat #

WHO PACKAGE INSERT. GlaxoSmithKline Biologicals FluLaval. Dossier First - Chapter 1 to 10 for WHO

The humoral immune responses to IBV proteins.

Centers for Disease Control and Prevention U.S. INFLUENZA SEASON SUMMARY*

Modeling the Antigenic Evolution of Influenza Viruses from Sequences

HAI and NAI as Correlates of Protection After Influenza Vaccination

Laboratory Diagnosis of Avian Influenza and Newcastle Disease

Recommended laboratory tests to identify influenza A/H5 virus in specimens from patients with an influenza-like illness

Influenza A IgG ELISA

SEROLOGICAL DIAGNOSIS OF VIRAL INFECTIONS:

E. Histolytica IgG (Amebiasis)

J07 Titer dynamics, complement fixation test and neutralization tests

Human Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set

Hemagglutinin-stalk specific antibodies: How to induce them and how to measure them

Human Influenza A (Swine Flu) Rapid test

Supplementary Appendix

Reassortment of influenza A virus genes linked to PB1 polymerase gene

Review on vectored influenza vaccines. Sarah Gilbert Jenner Institute Oxford

Biotechnology-Based Vaccines. Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:

ACTG Laboratory Technologist Committee Revised Version 2.0 ACTG Lab Man Coulter HIV-1 p24 ELISA May 21, 2004

Influenza Genome Sequencing Project Proposal

Recommended composition of influenza virus vaccines for use in the influenza season

What is Influenza? Patricia Daly MD, FRCPC Medical Health Officer and Medical Director of Communicable Disease Control

Rapid-VIDITEST Swine Flu

Mouse Adiponectin Immunoassay Kit

Lars R. Haaheim ( ) PhD, Professor Emeritus, University of Bergen, Norway

Preparation and properties of a novel influenza subunit vaccine G. SCHMIDT* H. BACHMAYER E. LIEHL. guinea-pigs, s.c. and i.m. for rabbits.

STUDIES UPON THE POSSIBILITIES OF AVIAN INFLUENZA VIRUSES CULTIVATION IN CHICK EMBRYOS AT DIFFERENT AGE

Novartis Vaccines and Diagnostics S.r.l

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON HARMONISATION OF REQUIREMENTS FOR INFLUENZA VACCINES

Flu, Avian Flu and emerging aspects (H1N1 resistance)

7/14/2014 VACCINE-INDUCED ANTI-HA2 ANTIBODIES PROMOTE VIRUS FUSION AND ENHANCE INFLUENZA VIRUS RESPIRATORY DISEASE (VAERD)

HIV-1 p24 Antigen ELISA Catalog Number:

however, and the present communication is concerned with some of

Original Article Development and Sequence Analysis of a Cold-Adapted Strain of Influenza A/New Caledonia/20/1999(H1N1) Virus

Human Influenza. Dr. Sina Soleimani. Human Viral Vaccine Quality Control 89/2/29. November 2, 2011 HVVQC ١

This kit is intended for Research Use Only. Not for use in diagnostic procedures.

Cover Page. The handle holds various files of this Leiden University dissertation

SIV p27 Antigen ELISA Catalog Number:

Q: If antibody to the NA and HA are protective, why do we continually get epidemics & pandemics of flu?

Blocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model

CONSISE workshop on influenza NA and discussion of an international study of the ELLA NA inhibition assay

Identification of New Influenza B Virus Variants by Multiplex Reverse Transcription-PCR and the Heteroduplex Mobility Assay

Antigenicity of Influenza Vaccine from Bovine Cell Cultures

Studying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID

SYNOPSIS. Individual Study Table Referring to Part of the Dossier. FluvalAB-H-YL2013

Influenza viruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics

Avian influenza and pandemic threats

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update

Acute respiratory illness This is a disease that typically affects the airways in the nose and throat (the upper respiratory tract).

Trichinella Cat #

Clinical Trial result: Page 1 / 6

The development of H7N9 influenza vaccine in Taiwan and the strategy for universal flu vaccine design against influenza

Human HBcAb IgM ELISA kit

ab Anti-Influenza virus A IgG Human ELISA Kit

Immobilized Virions, and Mixed Hemadsorption

Please use only the valid version of the package insert provided with the kit.

EXOTESTTM. ELISA assay for exosome capture, quantification and characterization from cell culture supernatants and biological fluids

hemagglutinin and the neuraminidase genes (RNA/recombinant viruses/polyacrylamide gel electrophoresis/genetics)

Transcription:

Borgis New Med 2015; 19(4): 147-155 DOI: 10.5604/14270994.1191796 Detection of neuraminidase-inhibiting antibodies for measurement of Influenza vaccine immunogenicity *Mónika Rózsa 1, István Jankovics 1, Ildikó Visontai 1, István Barcs 2 1 National Centre for Epidemiology, Budapest, Hungary Head of Centre: Márta Melles, MD 2 Department for Epidemiology, Institute of Health Promotion and Clinical Methodology, Faculty of Health Sciences, Semmelweis University, Budapest, Hungary Head of Department: prof. István Barcs, MD, PhD Summary Introduction. The HA and NA proteins are in the lipid envelope of virions. The HA and NA are an integral membrane proteins and its neuraminidase activity is required for efficient release of viral particles from the infected cell. Neuraminidase activity might be measured by neuraminidase inhibition assay. Aim. The present study is aimed at testing the usability of a new method which allow for the detection and quantification of neuraminidase inhibiting antibodies. Material and methods. The results of the four methodologies were compared with each other: Takátsy-assay, ELISA-microneutralization assay, CPE-microneutralization assay and new neuraminidase inhibition (NI) assay lectin peanut agglutinin conjugated peroxidase (PNA) technique. Haemagglutinin inhibition is a traditional method was used as the gold standard in our investigations. Human sera have been used in our studies which obtained from vaccinated people. Inactivated seasonal influenza vaccines have been in development for over 50 years in Hungary. Inactivated vaccines contain a trivalent mixture of inactivated strains of the influenza viruses likely to circulate during the next influenza season. Inactivated whole-virus influenza vaccine is administered intramuscularly. After vaccination the humoral antibody levels are detected against to influenza virus surface antigens: haemagglutinin (HA), neuraminidase (NA) virus-specific neutralizing antibodies to influenza viruses. Results. After seasonal vaccination induced neuraminidase inhibiting (NI) serum antibody titers detected by PNA and the Takátsy-assay are correlated. PNA assay is a very sensitive assay, resulting in significantly higher NI titers as compared to the Takátsy-assay. NI serum titers detected by PNA and haemagglutinin inhibiting titers are highly correlated. Conclusions. This new NI method is useful to better standardize influenza vaccines immunological requirements prior to their commercialisation and it can be usefully assay in microbiological labs, as it is very easy to standardize. Keywords: inactivated influenza vaccines, haemagglutinin, neuraminidase, Takátsy-assay, PNA assay Introduction There are two external glycoprotein components coded by virus genome on the surface of influenza virus particles. The HA protein is responsible for attachment and infection of the host cell and is the most immunogenic protein of the virus (1). The present study is aimed at testing the usability of a new method which allow for the detection and quantification of NA antibodies. Neuraminidase is an enzyme on the surface of influenza viruses that cleaves terminal sialic acid from sugar residues and from glycoproteins and so releases virus from the infected cells. Neuraminidase activity might be mesured by NI assay. This assay is based upon enzymatic removal by NA of the sialic acid residual of the fetuin. When a neuramindase substrate is coated on to the wells of a microplate and peroxidase conjugated peanut agglutinin recognizes and binds the free galactose, it is possible to quantitate the binding of PNA. The amount of bound PNA correlated directly with te amount of sialic acid removed from the substrate and therefore with the neuraminidase activity (2, 3). Neuraminidase inhibition (NI) test is used for the titration of antibodies against neuraminidase antigen in human sera. By reacting with specific epitopes that are located near to the enzyme active site, anti-neuraminidase antibodies are capable of inhibiting the virus induced desialylation of the substrate. Such antibodies therefore reduce the binding of peroxidase conjugated peanut agglutinin. 147

Mónika Rózsa et al. Aim The present study is aimed at testing the usability of a new method which allow for the detection and quantification of NA antibod ies. Material and methods Virus preparations (4): The following virus strain were grown in 10 day-old embrionated chicken eggs: A/New Caledonia/20/99 (H1N1)-like strain (A/New Caledonia/20/99 [IVR-116]), A/Wisconsin/67/2005 (H3N2)-like strain (A/Wisconsin /67/2005 [NYMC X-161]), B/Malaysia/2506/2004-like strain (B/Malaysia/2506 /2004). Preparation of hyper immune sera: Chickens were immunized intravenously and boosted 3 weeks later. Whole blood was obtained by cardiac puncture approximately 4 weeks after the boost and sera stored at -20 C. The chicken antisera were specific for the inoculating strain as demonstrated by HA and NA inhibition assay. Haemagglutination inhibition test (HI) (5): HA was quantified based on a method described by Hirst (1942) (6) and then later modified by Salk (1944) (7). This traditional method for identifying subtype of influenza isolates, and is usually more rapid than serological diagnosis. The microneutralization assay (VN) (5): This test is a highly sensitive and specific assay for detecting virusspecific neutralizing antibodies to influenza viruses. The VN test was evaluated by ELISA or CPE (Cytopathogenic Effect) assay. Neuraminidase inhibition assays (NI): NI test is used for the titration of antibodies against neuraminidase antigen in human sera. Neuraminidase is an enzyme on the surface of influenza viruses that cleaves terminal sialic acid from sugar residues and from glycoproteins and so releases virus from the infected cells. Takátsy-assay (8): The NA activity and NI (9) micromethod assay based on Warren s colour reaction (9) that modified later by Takátsy and Barb (1978). Standard TBA Assay: Neuraminidase-inhibition by antibody is measured according to the thiobarbituric acid (TBA) assay for the free sialic acid released from fetuin in solution. A colour development is measured. Peroxidase-conjugated Lectin Peanut Agglutinin assay (PNA): Using fetuin as a substrate neuraminidase activity can be mesured (10). After the coating of fetuin on 96-well plates sera and standardised amount of viruses are mixed and added to the wells. After incubation and wash PNA is added, it binds to free galactose and is detected using an enzyme-linked immunosorbent assay. The amount of PNA that is bound is proportional to the amount of neuraminidase that is present. Changes in the NI titers of sera collected before and after vaccination with influenza virus can be observed. In 1995, a private Hungarian company, Omninvest Ltd. received a national marketing authorization for flu vaccine produced by the use of the same method, containing inactivated whole virus and AlPO4 as an adjuvant. In this report, we used following procedure. The 96- -weel microplates coated with fetuin (50 µg/ml in 0.1 M Carbonate-Bicarbonate Buffered Solution), 150 µl/well overnight at +4 C or 1 hour + 37 C. Wash with 350 µl/well PBS Buffer containing 0.5% TWEEN 20. The viruses must be standardized to have a 4 x OD value of the blank. Dilute viruses 2-scale and add 100 µl to each well overnight at +37 C and wash. Add 100 µl PNA (2 µg/ml in PBS) to each well and incubate 1 hour in room temperature. After washing add 100 µl OPD + UREA (substrate) to each well and the reaction then stopped by adding 100 µl/well 1N H 2 SO 4. Read results on 492-620 nm by ELISA-Reader. Neuraminidase inhibition test: the sera ere diluted a 2-scale in PBS. A mixture of 50 µl of standardized viral suspension and 50 µl of diluted serum, overnight at +37 C and wash. Result of the PNA and OPD + UREA reaction measured were made ELISA reader as well as the virus standardization assay. Results The results of the four methodologies were compared with each other and with the HAI assay. HAI assay was used as the gold standard in our investigations. ELISA virus neutralization test and PNA NI test was the most sensitive methods and these tests are more objective results. There is a comparative study between NI Takátsy spectrophotometric methodology and the PNA system. The test results correlate with each other (tab. 1). Thus 8 sera-pairs were role of PNA method in the N1 specific test. 7 sera pairs showed seroconversion. Top of results proved in No. 2, 4, 6, 7 and 8. The No. 9 serapair was not shown titer increase. 6 sera pairs showed seroconversion in the N2 specific test. Top of results proved in No. 3, 4, 5, 6, 8. No. 9 sera-pair was not shown titer increase. 5 sera pairs showed seroconversion in the B specific test. Top of results proved in No. 6, 7, and 8. No. 9 serapair was not shown 4-times titer increase as it is N1, N2 specific NI test. No. 4, 6, 7 and No. 8 sample pairs had NI responses induced after seasonal influenza vaccination for all three (N1, N2, B) against influenza subtypes. In the N1, N2 and B specific tests of PNA-POD (ELI- SA) there were 9 sera-pairs. In the N1 specific test there was a few of sera in No. 1 sera-pair for assay. Thus 8 sera-pairs were role of this method. 7 sera pairs showed seroconversion. In the results of pre-vaccination sera (No. 2-No. 9) were observed about 40 dilution values. In contrast the results of postvaccination sera were observed between 40-1280 dilu- 148

Detection of neuraminidase-inhibiting antibodies for measurement of influenza vaccine immunogenicity Table 1. Comparison NI titers of the sera pairs with PNA test and Takátsy-NI methods. Virus strain 1 2 3 NAI titers PNA-POD (ELISA) 4 5 6 7 8 9 N1 */1280 40/640 40/160 40/640 40/320 40/1280 40/640 80/1280 < 40/< 40 N2 < 40/80 1280/1280 160/640 < 40/160 160/640 640/2560 640/640 40/640 160/160 B 160/640 320/640 160/320 80/640 320/640 160/1280 40/1280 80/1280 80/160 Virus strain 1 2 NAI titers Spectrophotometric detection (Takátsy) 3 4 5 6 7 8 9 N1 */* 2/16 2/8 2/4 2/8 2/16 2/8 2/8 2/4 N2 1/1 8/16 8/8 1/1 1/8 4/16 4/8 1/8 4/4 B 0/0 8/64 16/32 4/32 16/32 16/128 1/128 8/64 8/16 N1 A/New Caledonia/20/99 (H1N1)-like strain (A/New Caledonia/20/99 [IVR-116]); N2 A/Wisconsin/67/2005 (H3N2)- -like strain (A/Wisconsin/67/2005 [NYMC X-161]); B B/Malaysia/2506/2004-like strain (B/Malaysia/2506/2004); 1-9 number of samples; serum pairs (pre-vaccination serum/collected serum 2 weeks after vaccination); *few serum Fig. 1. Comparison of the results of the four test methods showed seroconversion (four-time titer increase between first and second sera) observed in results of the No. 2 and No. 6 sample pairs in all laboratory assay. No. 9 sera-pair was not shown 4-times titer increase. The correlation coefficient value of ~ 0.8 indicates that there is significant association between the HI and PNA method. 149

Mónika Rózsa et al. tion values. Top of results proved in No. 2 (40/640), No. 4 (40/640), No. 6 (40/1280), No. 7 (40/640), and No. 8 (80/1280). No. 9 sera-pair was not shown titer increase. In the N2 specific test were 6 sera pairs showed seroconversion. In the results of pre-vaccination sera (No. 1-No. 9) were observed between 80-1280 dilution values. In contrast the results of post-vaccination sera were observed between 80-2560 dilution values. Top of results proved in No. 3 (160/640), No. 4 (< 40/160), No. 5 (160/640), No. 6 (640/2560), No. 8 (40/640). No. 9 sera-pair was not shown titer increase. In the B specific test were 5 sera pairs showed seroconversion. In the results of pre-vaccination sera (No.1- No. 9) were observed 40-320 dilution values. In contrast the results of post-vaccination sera were observed between 160-1280 dilution values. Top of results proved in No. 6 (160/1280), No. 7 (40/1280), and No. 8 (80/1280). No. 9 sera-pair was not shown 4-times titer increase (80/160) as it is N1, N2 specific test. No. 4, No. 6, No. 7, and No. 8 sample pairs had NI responses induced after seasonal influenza vaccination for all three (N1, N2, B) against influenza subtypes. In the N2 and B specific tests of Takátsy-spectrophotometric detection methodology there were 9 serapairs. In the N1 specific test there was a few of sera in No. 1 sera-pair for assay. Thus 8 sera-pairs were role of this method. 6 sera pairs showed seroconversion (fig. 1). In the results of pre-vaccination sera (No. 2-No. 9) were observed 2 dilution values. In contrast the results of post-vaccination sera were observed between 4-16 dilution values. Top of results proved in No. 2 (2/16) and No. 6 (2/16). No. 4 and 9 sera-pairs were not shown 4-times titer increase (2/4) (fig. 2). Results of spectrofotometric detection Results of PNA (ELISA) Comparison of seroconversion Fig. 2. Comparison N1 specific NI titers of the sera pairs obtained with PNA test and Takátsy-methods. There is a significant difference between the PNA and Takátsy test. The NI titers are different significantly from pre-and post-vaccination sera. There are 4-times or high than 4-times rate of increase in titers with the exception of No. 9 sample-pair. The correlation coefficient value of 0.5 indicates which is a weak relationship between the two test results. Low correlation coefficient can be explained by the PNA- -POD assay found a higher titer differences. 150

Detection of neuraminidase-inhibiting antibodies for measurement of influenza vaccine immunogenicity In the N2 specific test were 3 sera pairs showed seroconversion. In the results of pre-vaccination sera (No. 1-No. 9) were observed between 1-8 dilution values. In contrast the results of post-vaccination sera were observed between 1-16 dilution values (fig. 3). Top of results proved in No. 5 (1/8), No. 6 (4/16), No. 8 (1/8). No. 1, 2, 3, 4, 7 and 9 serapairs were not shown titer increase (1/1, 8/16, 8/8, 1/1, 4/8, 4/4). In the B specific test there was a few of sera in No. 9 sera-pair for assay. 5 sera pairs showed seroconversion. In the results of pre-vaccination sera (No. 1-No. 8) were observed between 1-16 dilution values. In contrast the results of post-vaccination sera were observed between 16-128 dilution values. Top of results proved in No. 1 (8/64), No. 3 (4/32), No. 5 (16/128), No. 6 (1/128), No. 7 (8/64). No. 2, 4 sera-pairs were not shown 4-times titer increase. No. 5, No. 6, No. 8 sample pairs had NI responses induced after seasonal influenza vaccination for all three (N1, N2, B) against subtypes. N1 specific tests Comparison N1 specific NI titers of the sera pairs obtained with the different test methods. VN test and PNA- -POD test can be read with ELISA reader which allows objectively assessment. The Takátsy NI and CPE-VN test methods are highly subjective because these cannot be read by ELISA reader. The correlation coefficient value of 0.774132 indicates that there is significant association between the HAI (gold standard method) and PNA-POD method (fig. 1, fig. 2). Fig. 3. Comparison N2 specific N2 titers of the sera pairs obtained with the different test methods. VN test and PNA-POD test can be read with ELISA reader which allows objectively assessment. The Takátsy N2 and CPE-VN test methods are highly subjective because these cannot be read by ELISA reader. 151

Mónika Rózsa et al. N2 specific tests Comparison of the results of the four test methods showed seroconversion (four-time titer increase between first and second sera) observed in results of the No. 5 sample pairs in all laboratory assay. No. 9 serapair also was not shown 4-times titer increase such as the N1 specific NI assay. We found no high titer differences between the first and second sera in contrast N1-specific NI tests were shown extremely high titer differences. The correlation coefficient value of 0.7 indicates that there is significant association between the HI (gold standard method) and PNA method. The correlation coefficient value was similar (0.8) in the N1- specific NI assays. There is a significant difference between the PNA and Takátsy test. The NI titers are different from pre- and post- -vaccination sera. There are 4-times or high than 4-times rate of increase in titers of No. 5, 6, 8 samplepairs in both of test. There was no increase in titer for No. 2, 7, 9 sample-pairs in none of test. The correlation coefficient approaches to 1: value of 0.96 indicates that there is a significant correlation between the two methods (fig. 4). B specific test Comparison of the results of the four test methods showed seroconversion (four-time titer increase between first and second sera) observed in results of the No. 4 and 8 sample pairs in all laboratory assay. No. 5 and 9 sera-pairs was not shown 4-times titer increase. Titer differences were not found in any tests, under investigation of the No. 9 sample pair. We found high titer differences between the first and second sera as well as N1-specific NI tests were also shown extremely high titer differences (fig. 5). The correlation coefficient value of 0.67 indicates that there is significant association between the HI (gold standard method) and PNA method. The correlation coefficient values Results of spectrofotometric detection Results of PNA (ELISA) Comparison of seroconversion Fig. 4. Comparison N2-specific NI titers of the sera pairs obtained with PNA test and Takátsy-NI methods. 152

Detection of neuraminidase-inhibiting antibodies for measurement of influenza vaccine immunogenicity Fig. 5. Comparison B specific NI titers of the sera pairs obtained with the different test methods. VN test and PNA test can be read with ELISA reader which allows objectively assessment. The Takátsy NI and CPE-VN test methods are highly subjective because these cannot be read by ELISA reader. observed against N2 influenza vaccine strains that is part of the seasonal trivalent influenza vaccine and 66% seroconversion by PNA assay, 33% by Takátsy assay. The humoral immune response was around 89% against B influenza vaccine strain by HI assay and 56% seroconversion by PNA assay, 56% by Takátsy assay. The NI antibody responses are significantly induced after vaccination. Highest prevalence rates of NI seroconversion are induced N1 specific NI responses and the lowest proportion of of seroconversion are induced B specific NI responses. There is 4 x differences between the first and second serum titers for both of methodology. The PNA system is much more sensitive and there is an implementation method is simpler and cheaper. Tenth part of sample volume is required for the PNA test compared to Takátsy method. The standardization of viruses is enough amniwere 0.8 in the N1-specific NI assay and 0.7 in the N2- specific NI assay. There is a significant difference between the PNA and Takátsy-NI test. The NI titers are different from pre-and post-vaccination sera. There are 4-times or high than 4-times rate of increase in titers of No. 4, 6, 7, 8 samplepairs in both of test. There was no increase in NI titer for No. 3, 5, 9, sample-pairs in none of test. The correlation coefficient approaches to 1: value of 0.91 indicates that there is a significant correlation between the two methods (fig. 6). Discussion HI antibody responses are significantly induced after vaccination (fig. 7). It was around 75% seroconversion by HI assay against strain N1 of the trivalent seasonal influenza vaccine and 87.5% seroconversion by PNA assay, 66% by Takátsy assay. Around 45% seroconversion was 153

Mónika Rózsa et al. Results of spectrofotometric detection Results of PNA (ELISA) Comparison of seroconversion Fig. 6. Comparison B-specific NI titres of the sera pairs obtained with PNA test and Takátsy-methods. Conclusions After seasonal vaccination induced NI serum titers detected by PNA and the Takátsy-assay are correlated. PNA assay is a very sensitive assay, resulting in significantly higher NI titers as compared to the TBA assay. NI serum titers detected by PNA and HI titers are highly correlated. PNA technique can be useful assay in microbiological labs, as it is very easy to standardize. Acknowledgement National Centre for Epidemiology; Department of Respiratory viruses staff. Fig. 7. Seasonal vaccination induced HI responses and HI seroconversion. otic and allantoic fluid, unlike Takátsy s system in which is required for the concentrated virus strains and it is more expensive and time-consuming method. References 1. Lamb RA, Krug RM.: Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE et al., editors. Fields Virology, 4 th ed. Lippincott Williams & Wilkins. 2001: 1487 1531. 2. Montomoli E et all.: A method for detection of neuraminidase antibody in serum. International Congress Series. 2004: 1263. 3. Lambré CR, Terzidis H, Greffard A, and Webster RG.: Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtiter 154

Detection of neuraminidase-inhibiting antibodies for measurement of influenza vaccine immunogenicity plates coated with natural substrates. Journal of Immunological Methods. 1990: 135: 49-57. 4. Gyula T.: A purified precipitated virus obtained by a new, simple method. Acta Microbiol. Hung. 1953 5. WHO Global Influenza Surveillance Network: Manual for the laboratory diagnosis and virological surveillance of influenza. 2011. 6. HYPERLINK "http://www.ncbi.nlm.nih. gov/pubmed/?term=hirst%20gk%5bauth%5d" Hirst GK.: Adsorption of influenza hemagglutinins and virus by red blood cells. HYPERLINK "http:// www.ncbi.nlm.nih.gov/pmc/journals/483/"j. Exp. Med. 1942:HYPERLINK "http://www.ncbi.nlm.nih.gov/pmc/issues/156529/" 76(2). 7. Salk, J.: A simplified procedure for titrating hemagglutinating capacity of influenza virus and the corresponding antibody. J. Immunol. 1944. 87-98. 49(2). 8. Gyula T, Barb K.: Adaptation of the influenza neuraminidase and neuraminidase-inhibition assays to the microtitrator system. Acta microbial. Acad Sci. hung. 1979: 63-69. 26. 9. Warren, L.: The thiobarbituric assay of sialic acids. J. Biol. Chem. 1959. 1971-1975. 234. 10. Aymard- Henry M, Coleman MT, Dowdle WR, Laver WG, Schild GC, Webster RG.: Influenzavirus neuraminidase and neuraminidase-inhibition test procedures. Bull World Health Organ. 1973. 199 202. 48(2). Received: 09.11.2015 Accepted: 23.11.2015 Correspondence to: *Mónika Rózsa National Centre for Epidemiology Department of Respiratory Viruses Albert Flórián (former Gyáli) út 2-6, H-1097 Budapest, Hungary tel.: +36 476-1100/2128 e-mail: rozsa.monika@oek.antsz.hu 155